Edwards Lifesciences Corporation (EW) is a publicly traded company in the Healthcare — Medical - Devices industry listed on NYSE. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions.
Analysis Summary
Edwards Lifesciences Corporation reported revenue of $6.07B in the most recent fiscal year, growing at a 5-year CAGR of 6.7%. Net income reached $1.07B, with a 5.4% 5-year CAGR.
Trailing-twelve-month margins: gross margin 78.0%, operating margin 28.1%, net margin 15.4%. Free cash flow grew at 15.6% CAGR over 5 years.
At the current price of $89.28, EW trades at a P/E of 49.28 and an ROE of 9.69%. Market capitalisation stands at $51.4B, placing it among large-cap names.
Balance sheet quality for EW: current ratio of 3.7, net cash position of $3.52B. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Cash flow quality is strong: free cash flow of $1.33B represents 124% conversion of reported net income. High conversion (above 90%) suggests earnings translate cleanly into cash; lower conversion may indicate working capital tightness or accounting timing differences.
Price
| Price | $89.28 |
| Market Cap | $51.4B |
| Exchange | NYSE |
| Country | US |
Valuation Ratios
| P/E Ratio | 49.28 |
| Price / Book | 4.65 |
| EV / EBITDA | 31.96 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 9.69% |
| Return on Invested Capital | 10.20% |
| Return on Assets | 7.25% |
| Gross Margin | 77.98% |
| Operating Margin | 28.09% |
| Net Margin | 15.43% |
Financial Health
| Debt / Equity | 0.07 |
| Current Ratio | 4.52 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 11.63 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| EW | Edwards Lifesciences Corporation | $49.6B | 49.28 | 4.65 | 9.7% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| DXCM | DexCom, Inc. | $33.2B | 33.38 | 12.65 | 36.2% |
| BRKR | Bruker Corporation | $8.4B | 3.74 | -2.9% | |
| BDX | Becton, Dickinson and Company | $49.0B | 54.89 | 2.05 | 3.8% |
| CAH | Cardinal Health, Inc. | $54.5B | 30.94 | -59.7% | |
| HLN | Haleon plc | $40.5B | 18.64 | 1.84 | 9.9% |
| ALC | Alcon Inc. | $32.2B | 51.85 | 1.52 |
Price Performance
| 1 month | -1.87% |
| 3 months | +2.20% |
| Year-to-date | +4.73% |
| 1 year | +18.72% |
| 3 years | +22.40% |
| 5 years | -25.24% |
52-Week Range
| 52-week High | $96.29 |
| 52-week Low | $72.30 |
| Avg Volume (90d) | 4.4M |
Related companies: A · ALC · ARGX · BDX · BRKR · CAH · DXCM
Explore sector: Healthcare · Medical - Devices
More sections of EW: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks